Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly

This early-phase trial is testing whether adding the targeted drug polatuzumab vedotin (with or without another drug called glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to se…

This study tests the drug pembrolizumab in people with certain aggressive lymphomas or rare histiocyte/dendritic cell cancers that have come back or not responded to treatment. The goal is to see if the drug can shrink tumors. The study is currently suspended and enrolled 18 part…

This study tests whether adding the drug venetoclax to standard chemotherapy can keep high-grade B-cell lymphomas from returning or getting worse. The trial includes 363 people with aggressive lymphoma subtypes. Venetoclax targets a protein that helps cancer cells survive, while …

This study is for people aged 75 or older who have been newly diagnosed with certain aggressive types of B-cell lymphoma. It tests whether adding an oral medication (CC-486, or oral azacitidine) to the standard reduced-dose chemotherapy regimen (R-miniCHOP) can help keep the canc…

This phase 3 study tests whether adding the experimental drug golcadomide to standard R-CHOP chemotherapy helps people with untreated high-risk large B-cell lymphoma live longer without their cancer worsening. About 850 adults will be randomly assigned to get either golcadomide o…

This phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to treatment. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the combin…

This study tests a combination of two drugs, tafasitamab and lenalidomide, in adults with diffuse large B-cell lymphoma that has come back or not responded to prior treatments. Participants have had 1 to 3 previous therapies but cannot receive high-dose chemo or a stem cell trans…

This phase 2 study tests whether adding the drug acalabrutinib to the CAR T-cell therapy lisocabtagene maraleucel (liso-cel) can improve outcomes for people with aggressive B-cell lymphomas that have come back or not responded to treatment. About 28 adults will receive acalabruti…

This phase 3 trial tests whether adding decitabine to standard chemotherapy (R-CHOP) helps people with a specific, aggressive lymphoma tied to the Epstein-Barr virus. About 80 newly diagnosed patients will be randomly assigned to get either the new combo or standard treatment alo…